Most Read

In addition, Zymeworks granted BeiGene a license to Zymeworks’ proprietary Azymetric and EFECT platforms to develop and commercialize globally up to three other bispecific antibodies using the platforms.

To fill their drug pipelines, large pharmaceutical and biotechnology companies are buying promising drug compounds that have been developed by small biotech companies up to the point of

The companies will advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies. Through a

This approval is an important achievement for the company and most importantly, represents major progress for patients and physicians. Octapharma board member Olaf Walter said: “The development of

This second part of the Phase 1a study will enroll six healthy subjects per group, with a primary objective to assess safety and tolerability and a secondary objective

A total of 186 patients have been enrolled into the study, surpassing the Company’s initial target of 174 patients. The increased enrolment numbers followed high engagement from study

Tessa Therapeutics (Tessa), an international clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, is a leading developer of personalized T cell therapies for solid tumors,

This marks the first approval of a long-acting treatment for opioid dependence in the EU. London’s King’s College National Addiction Centre director professor Sir John Strang, said: “Patients

The research collaboration brings together Evotec’s leading induced pluripotent stem cell (iPSC) platform and broad drug discovery capabilities with Immuneering’s unique artificial intelligence-driven drug discovery platform to accelerate